The rndx mouse containing a nonsense point mutation in the dystrophin gene is a genetic model for human DMD (1). The mouse has increased serum creatinine phosphate kinase levels and muscle pathology that includes necrosis, cellular infiltration, wide range of fiber size, and a large number of centrally nucleated fibers. In contrast to DMD, fibrosis and fatty deposits are not typical for rndx skeletal muscle. Nonetheless, the rndx mice have been helpful for increasing our understanding of DMD by elucidating the role of the dystrophin-associated glycoproteins (2) and the role of elevated myofiber calcium in its pathogenesis (3-5). An understanding of why the rndx mouse is different from human DMD may prove critical to the development of a successful therapy (6). A recent report indicates that rndx diaphragmatic muscle has pathology similar to human muscle (7).
The rndx mouse containing a nonsense point mutation in the dystrophin gene is a genetic model for human DMD (1) . The mouse has increased serum creatinine phosphate kinase levels and muscle pathology that includes necrosis, cellular infiltration, wide range of fiber size, and a large number of centrally nucleated fibers. In contrast to DMD, fibrosis and fatty deposits are not typical for rndx skeletal muscle. Nonetheless, the rndx mice have been helpful for increasing our understanding of DMD by elucidating the role of the dystrophin-associated glycoproteins (2) and the role of elevated myofiber calcium in its pathogenesis (3) (4) (5) . An understanding of why the rndx mouse is different from human DMD may prove critical to the development of a successful therapy (6) . A recent report indicates that rndx diaphragmatic muscle has pathology similar to human muscle (7) .
New mutant alleles of rndx were recovered from female progeny of ethylnitrosourea-treated male mice that are designated mdx2", mdx3'', and mdx4" (8) . More recently, we have established a fourth allele, mdx5"". The location of these new mutations has been established relative to a restriction fragment length polymorphism in the central region of the gene, such that mdxTV, -3'", and -4'" map to the 3' region of dystrophin gene, whereas mdx5" maps to the 5' region (Chapman VM, Miller DR, unpublished data). These new rndx mutants lacked dystrophin in skeletal muscle as assayed by immunofluroescence and immunoblots and had skeletal muscle pathology similar to the original rndx mice.
A small percentage of the skeletal and cardiac muscle cells in rndx mice and humans with DMD contain dystrophin immunoreactivity against the background of dystrophin-negative cells (9) . The nature of the dystrophin-positive cells referred to as revertants has yet to be determined. Postulated mechanisms for the revertants include 1 ) genomic deletion of the exon containing the point mutation, 2) expression of a suppressor transfer RNA, and 3) expression of dystrophin-related protein.
The ability of the revertants in the rndx mice to be stained with several different antibodies that recognized all of the dystrophin domains suggested that the revertants were expressing the X chromosomeencoded dystrophin protein. The expression of a dystrophinrelated protein was altered in rndx mice, but its pattern of expression was different from that of the revertants (10, 11) . The rndx mouse has played a critical role in the development of new cellular transplantation and gene therapies (12, 13) . The number of dystrophin-positive muscle cells before and after the experimental maneuvers is useful for assessing the efficacy of these experimental therapies. The presence of the revertants complic~tes this assessment. This study found that the mdx4'' and mdx5"' mutants contained approximately 10-fold fewer revertants than the rndx mutants.
MATERIALS AND METHODS
Mouse strains. Mdx mice (C57BL/10 mdx/mdx) and control BALB/c mice were obtained either from Jackson Laboratories (Bar Harbor, ME) or from V. Chapman's laboratory, which obtained the rndx mice directly from G. Bulfield's laboratory. The mdx2", mdx3", mdxCV, and mdx5"' mutants were initially bred to congenicity onto the C57BL/6Ros background for more than 10 generations (8) and were subsequently maintained in both the Buffalo and Madison laboratories.
Dystrophin assays. Immunoblots were performed as previously reported using the 6-10 antibody (1 3, 14) . After staining for dystrophin, the blots were stained with india ink to determine the amount of myosin that was transferred in each lane. Immunofluorescence analysis was performed on 6-pm frozen sections as previously reported (1 3) using 1-2a antibody directed against the amino terminus (15), affinity-purified 30-kd antibody directed against the rod domain (16), 6-10 antibody directed against another part of the rod domain (13) , and dl0 antibody against the carboxyl terminal domain (9, 16, 17 Statistical analysis was performed using t tests.
REVERTANTS IN mdx MOUSE DMD MODELS 129 RESULTS
Skeletal muscle. The quadriceps muscles of the mutants were analyzed by immunofluorescent staining for dystrophin. As previously reported (8) , the vast majority of the skeletal myofibers on the cross-sections from the mdx2, mdx5, and mdx4 mutants lacked dystrophin immunoreactivity. Unexpected results in the mdx3 mutant will be presented below. As in the rndx muscles, the skeletal muscles in the mdx2, mdx5, and mdx4 mutants had a few revertant fibers with dystrophin immunoreactivity at the sarcolemma. The most sensitive antibody, the 6-10 antibody, was used to reduce the chance of missing revertants with low levels of dystrophin (14) . A large muscle group such as the quadriceps was chosen because its high number of revertants would provide a critical assessment of the number of revertants in the animals (9) . Four to six quadriceps muscles were analyzed for each mutant. The number of revertants was counted in 10-20 sections of the middle part of the quadriceps, which contains approximately 4000 myofibers. The number of revertants among the different sections of the same muscle varied by less than 15 %. Figure 1 compares the mean number of revertants per quadriceps cross-section in the mdx, mdx2, mdx4, and mdx5 mutants at 2 and 6 mo. At 2 and 6 mo, both the mdx4 and mdx5 mutants had significantly fewer revertants than the rndx and mdx2 mutants (p < 0.05). At 2 mo of age, the mdx4 and mdx5 mutants had approximately 5-to 12-fold fewer revertants than the rndx and mdx2 mutants. At 6 mo of age, the mdx4 and mdx5 mutants also had 8-to 18-fold fewer revertants than the rndx and mdx2 mutants. From 2 to 6 mo, the number of revertants significantly increased (p < 0.05) 6.2-fold in mdx, 7.4-fold in mdx2, 4.0-fold in mdx4, and 4.6-fold in mdx5 mutants. In other muscles, such as the gastrocnemius, soleus, and diaphragm, the mdx4 and mdx5 mutants also had less revertants than the rndx and mdx2 mutants. Serial sections of the revertants in the mdx, mdx2, mdx4, and mdx5 mutants that were stained with the 6-10 antibody were also stained to some degree with the 1-2a, 30-kd, and d 10 antibodies.
Sections of the mdx3 quadriceps stained for dystrophin immunofluorescence with the 6-10 antibody revealed that all myofibers contained sarcolemmal, dystrophin immunofluorescence (Fig. 2B) . However, the intensity of the dystrophin staining was less than that in normal mice ( Fig. 2A) , but greater than the levels in the nonrevertant fibers of the other mutants (Fig. 2C ). An increased variability in the diameters of the myofibers from the mdx3 mice was also apparent. Other dystrophin antibodies (1-2a, 60-kd, and dl0) yielded similar results for the mdx3 mice.
In the mdx, mdx2, mdx4, and mdx5 mutants, approximately 70-90% of the nuclei in both the dystrophin-positive and dystrophin-negative myofibers were centrally located at 6 mo (n > 500 2 months of age 6 months of age T mdx mdx2 mdx4 mdx5 S t r a i n for each group). Greater than 70% of the mdx3 myofibers also contained central nuclei. Less than 1% of the myofibers from normal mice had central nuclei.
The diaphragms of rndx mice have substantially increased fibrosis, fatty infiltration, and necrosis with cellular infiltration than the skeletal muscles of the extremities (7) . The diaphragms of all four mutants contained amounts of fibrosis, fatty infiltration, and necrosis similar to those in the rndx muscle. The pathologic findings were more extensive with increasing age in all the mutants. As previously reported (8) , the pathologic findings of the skeletal and cardiac muscles in the four new rndx mutants were similar to those in the original rndx mice.
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Cardiac muscle. The number of revertants was evaluated in the myocardium of the mdx, mdx2, mdx4, and mdx5 mutants (Table 1) . Revertants were also present in cardiac tissue from 6-mo-old mdx3 mutants because, unlike their skeletal muscle cells, all their cardiac cells did not have dystrophin immunofluorescence. At both 2 and 6 mo, the total number of revertants and clusters of revertants was greater in the mdx2 mutants than in the other mutants.
In the mdx, mdx2, and mdx4 mutants, the number of revertants was similar at 2 and 6 mo. Revertants were not observed in the cardiac muscles from the mdx5 and mdx3 mutants at 2 mo, but were observed at 6 mo. Given the difficulty in accurately determining the number of cardiac revertants, more hearts from the mdx3 and mdx5 mutants must be analyzed to determine whether the numbers actually increase over time in these mutants.
Immunoblot analysis of skeletal and cardiac muscles. Immunoblots using the 6-10 antibody were performed on quadriceps and cardiac muscles from normal, BALB/c mice and the five mutants (Fig. 3) . After staining for dystrophin, the blots were stained with india ink to determine the approximate amount of protein transferred. Some of the lanes contained a band above dystrophin that most likely represents the cross-reaction of the 6-10 antibody with nebulin (13) . No band above dystrophin in size was observed in the heart extracts because cardiac tissue does not contain nebulin.
Dystrophin was not observed in skeletal muscles from the mdx, mdx2, mdx4, or mdx5 mutants (Fig. 3A, lanes 2, 3, 6 , and 7), but low levels were observed as a faintly staining band in the mdx3 mutants (Fig. 3A, lane 4) . These results were observed on more than 20 immunoblots on muscles from eight animals for each of the different mutants. Given the reproducibility of finding faint dystrophin staining in the mdx3 extracts and not in the other muscle extracts, it is unlikely that it was due to contamination. Ten immunoblots were performed on extracts from five hearts *The results are presented from three different sections, which contained the greatest number of revertants of the 10 sections examined. Each number represents the number of cells in each cluster of revertants. Each row is from a different animal. for each of the mutants (Fig. 3B) . Dystrophin was never observed in the mdx4 or mdx5 mutants (Fig. 3B, lanes I and 2) , but low and variable amounts were observed in half of the 10 immunoblots performed on the extracts of mdx2 or rndx hearts (Fig. 3B,   lanes 6 and 7) . This variable and very faint dystrophin staining may have been observed only in this study to date because of the use of the sensitive 6-10 antibody. If it was due to expression of the X-chromosomal dystrophin or a dystrophin-related protein, it is not clear why it was only observed in the heart extracts.
In 10 immunoblots from five hearts of mdx3 mice, faint dystrophin staining was consistently observed to be greater than that in the rndx or mdx2 mice (Fig. 3B, lane 4) .
DISCUSSION
The number of revertants in skeletal and cardiac muscle differed significantly among the mdx, mdx2, mdx3, mdx4, and mdx5 mutants. The rndx and mdx2 mutants both had the largest number of revertants with approximately 20 to 30 revertants per quadriceps cross-section at 2 mo of age, and approximately 200 revertants per quadriceps cross-section at 6 mo of age. The mdx4 and mdx5 mutants had approximately 10-fold fewer mutants than the rndx and mdx2 mutants at both 2 and 6 mo of age, with less than five revertants per quadriceps cross-section at 2 mo and less than 20 at 6 mo. The number of cardiac revertants was also greater in the rndx and mdx2 mutants than in the mdx5 or mdx3 mutants.
In the previous study, the number of revertants in rndx mice varied by at least 10-fold between the rndx mice maintained in the London and Boston laboratories (9) . Different genetic backgrounds of the Boston and London rndx mice may have been the cause of their different reversion rates. Because the mdx2, mdx4, and mdx5 mice were bred to congenicity onto the C57BL/ 6Ros background for more than 10 generations, it is highly unlikely that their different reversion rates were due to different To further expiore the dasis for the different reversion rates among the mutants, rndx mice have been bred with mdx5 mice to generate female heterozygotes. The differences in reversion rates among the mutants has potential implications concerning the mechanism and nature of the revertants.
The relatively larger number of revertants in the rndx mutants has complicated the analyses of gene or cell therapies. The high background increases the difficulty in assessing the efficacy of the new therapies based on the ability of the experimental therapy to increase the number of dystrophin-positive fibers. The few revertants in the mdx4 and mdx5 mutants indicates that these mutants will be useful for the evaluation of gene and cell therapy approaches in mice. The pathology in the quadriceps, cardiac, and diaphragm muscles of the mdx4 and mdx5 mutants indicates that they will be as useful as the original rndx mouse in this regard.
The faint dystrophin immunofluorescence at the skeletal sarcolemma in the mdx3 mutants is of interest. None of the other mutants had such faint sarcolemmal immunofluorescence. On immunoblot analysis, the skeletal muscle of the mdx3 mutants also had small amounts of dystrophin, whereas the mdx, mdx2, mdx4, and mdx5 mutants did not. The low dystrophin levels in the mdx3 mutants were not able to prevent the pathology of the skeletal or diaphragm muscles. Human DMD patients with similar low levels of dystrophin have been described, and the mdx3 mutant will be useful as a model for this class of dystrophic patients (19, 20) .
The hearts of the mdx3 mutants consistently had low levels of dystrophin on immunoblots, but their cardiac sarcolemma did not have dystrophin immunofluorescence. The sarcolemmal location of a mutated dystrophin in skeletal but not cardiac muscle has not been noted in humans previously, and its molecular basis is speculative. The mdx3 mutated dystrophin protein may be able to complex with dystrophin-associated proteins in skeletal muscle, but not in cardiac muscle (2), or perhaps the mdx3 dystrophin mRNA is spliced differently in cardiac and skeletal muscle (2 1).
